Comments on: Miles: U of M conflict-of-interest rules won’t stop next Grassley letter http://minnesotaindependent.com/51216/university-minnesota-conflict-interest-grassley-miles News. Politics. Media. Wed, 30 Nov 2011 23:48:28 +0000 hourly 1 http://wordpress.org/?v=3.1 By: don in mpls http://minnesotaindependent.com/51216/university-minnesota-conflict-interest-grassley-miles/comment-page-1#comment-46522 don in mpls Sun, 10 Jan 2010 17:02:28 +0000 http://minnesotaindependent.com/?p=51216#comment-46522 Rob, there was no regulation to begin with. putting a system in that functions and employing people to watch for these potential conflicts would be healthy for the system. (look at the SEC- no regulation and now we have all this hell at hand.) Rob,

there was no regulation to begin with. putting a system in that functions and employing people to watch for these potential conflicts would be healthy for the system.

(look at the SEC- no regulation and now we have all this hell at hand.)

]]> By: Robert Herndon http://minnesotaindependent.com/51216/university-minnesota-conflict-interest-grassley-miles/comment-page-1#comment-44630 Robert Herndon Tue, 08 Dec 2009 14:18:12 +0000 http://minnesotaindependent.com/?p=51216#comment-44630 Senator Grassley's bulldozer approach is throwing the baby out with the bathwater. The ties between academics and pharmaceutical companies has done much to improve their clinical drug trials and their approach to drug development. If you only look at the downside, ie improper marketing and improper promotion of drugs and devices by physicians you are only seeing a small portion of the picture. Over regulation is already driving clinical trials out of academic institutions into private clinics where there will be even less scrutiny Senator Grassley’s bulldozer approach is throwing the baby out with the bathwater. The ties between academics and pharmaceutical companies has done much to improve their clinical drug trials and their approach to drug development. If you only look at the downside, ie improper marketing and improper promotion of drugs and devices by physicians you are only seeing a small portion of the picture. Over regulation is already driving clinical trials out of academic institutions into private clinics where there will be even less scrutiny

]]>